These are exciting times for CoQ10 therapies as research, over the recent months, is increasingly linking its use to a whole host of potent health benefits, which extend far beyond energy, mitochondria and antioxidant support alone. Whilst these mechanisms are at the heart of this potent antioxidant’s far-reaching benefits, CoQ10 – specifically in the active ubiquinol form – is rapidly gaining nutritional ‘superhero’ status, from which most of us can elicit some significant health benefits.
The below studies are just a handful of those recently published linking the importance of the reduced form of CoQ10, ubiquinol, with an ever-increasing array of preventative and protective health effects. Each of these studies has specifically investigated the levels, or use, of ubiquinol compared with the ubiquinone form of CoQ10 and found it to be superior. When choosing a CoQ10 supplement for therapeutic and optimal wellbeing, it is important to seek out ubiquinol (products stating simply CoQ10 are usually ubiquinone) delivering at least 100mg per dose, as this is the minimum associated with positive outcomes in most recent clinical trials. Igennus VESIsorb Ubiquinol-QH was chosen and added to our therapeutic, practitioner focused product range due to its unique health benefits, bioavailability and absorption – aspects that are supported by considerable scientific evidence.
It’s been known for quite some time that CoQ10 levels are linked to sperm health and subsequently motility, but a recent study has confirmed this link, with a daily dose of 150mg ubiquinol being shown to increase sperm count by over 50%, and the quantity of rapidly motile sperm by 41%! Few could argue then that ubiquinol is a fantastic and important addition to a couple’s fertility support plan.
Acute inflammatory responses
A recent and large study conducted in Caucasians looked at C-reactive protein (CRP) levels and found that those with the lowest ubiquinol status, relative to their total CoQ10 levels, had the highest CRP levels also. Higher levels of oxidised CoQ10 (ubiquinone) levels were significantly associated with acute inflammatory markers, even after controlling for BMI and gender separately. The study authors concluded that availability of ubiquinol, and a low ubiquinol status, is linked to higher BMI and low-grade inflammation, which suggests that ubiquinol supplementation may be beneficial to those with, or at risk of, low ubiquinol status.
Statin induced liver dysfunction
Liver cell toxicity, although rare, is just one of the many severe side effects associated with long term statin use. Whilst the mechanisms are not 100% understood, CoQ10 status has been linked. The below study, published only weeks ago, found that supplementation with ubiquinol for 12 weeks was able to reduce markers of hepatocyte damage right down at the RNA level, adding much needed support to the argument for optimising ubiquinol status in statin users. Ubiquinol supplementation, in addition, regulated miRNAs that inhibit apoptotic and inflammatory pathways, suggesting potential hepatoprotective effects, which could offer benefits to other with liver dysfunctions, even if someone is not a statin user!
Metabolic complications and central adiposity
Oxidative stress in white adipocytes has been directly linked to subsequent cellular dysfunction and metabolic complications associated with high central adiposity. In this recent study researchers found, when compared with normal weight individuals, that ubiquinol levels were reduced in the abdominal fat of overweight individuals and that these cells were at increased risk of lipid peroxidation. Low total CoQ10 levels were also associated with higher total body fat, extent of central adiposity, circulating inflammatory cytokines and insulin resistance. These findings suggest that early intervention with CoQ10, as ubiquinol, could be an important preventative nutrient in the fight against the comorbidities associated with abdominal weight gain.
One recent double-blind, placebo-controlled pilot trial showed that 300mg daily of ubiquinol was able to significantly decrease unified Parkinson’s disease rating scale scores (a scale determining severity of symptoms) in patients experiencing Levodopa-related wearing off. CoQ10 levels were also significantly elevated, suggesting high dose ubiquinol might be important for improving treatment outcomes in Levodopa users. Ubiquinol was considered safe and well tolerated.